Get started
Author

Shayna Stein

Observed name: Shayna Renee Stein
ORCID: 0009-0008-3939-9019
Observed ORCID: 0009-0008-3939-9019
OpenAlex ID: A5063223919
Assessment of the cPAS-based BGISEQ-500 platform for metagenomic sequencing
2017 · Chao Fang, Huanzi Zhong, et al. · GigaScience · 412
PDF
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
2021 · Otto Metzger Filho, Giuseppe Viale, et al. · Cancer Discovery · 256
PDF
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer
2021 · Michalina Janiszewska, Shayna Stein, et al. · JCI Insight · 40
PDF
Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients
2018 · Shayna Stein, Rui Zhao, et al. · PLoS Computational Biology · 40
PDF
Detecting Allele-Specific Alternative Splicing from Population-Scale RNA-Seq Data
2020 · Levon Demirdjian, Yungang Xu, et al. · The American Journal of Human Genetics · 26
PDF
Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies
2019 · Kimiyo N. Yamamoto, Akira Nakamura, et al. · PLoS ONE · 15
Discover hidden splicing variations by mapping personal transcriptomes to personal genomes
2015 · Shayna Stein, Zhi-xiang Lu, et al. · Nucleic Acids Research · 12
PDF
Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
2023 · Yu-Chen Cheng, Shayna Stein, et al. · Cancer Research Communications · 8
PDF
Using RNA-Seq to Discover Genetic Polymorphisms That Produce Hidden Splice Variants
2017 · Shayna Stein, Emad Bahrami-Samani, et al. · Methods in molecular biology · 3
Supplementary Table S2 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
2023 · Yu-Chen Cheng, Shayna Stein, et al.
Supplementary Fig. S2 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
2023 · Yu-Chen Cheng, Shayna Stein, et al.
PDF
Supplementary Fig. S6 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
2023 · Yu-Chen Cheng, Shayna Stein, et al.
Supplementary Fig. S16 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
2023 · Yu-Chen Cheng, Shayna Stein, et al.
Supplementary Fig. S12 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
2023 · Yu-Chen Cheng, Shayna Stein, et al.
Supplementary Fig. S2 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
2023 · Yu-Chen Cheng, Shayna Stein, et al.
Supplementary Table S1 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
2023 · Yu-Chen Cheng, Shayna Stein, et al.
PDF
Supplementary Fig. S3 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
2023 · Yu-Chen Cheng, Shayna Stein, et al.
PDF
Supplementary Fig. S9 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
2023 · Yu-Chen Cheng, Shayna Stein, et al.
TABLE 2 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
2023 · Yu-Chen Cheng, Shayna Stein, et al.
Supplementary Table S3 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
2023 · Yu-Chen Cheng, Shayna Stein, et al.
PDF
Supplementary Table S3 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
2023 · Yu-Chen Cheng, Shayna Stein, et al.
Supplementary Fig. S4 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
2023 · Yu-Chen Cheng, Shayna Stein, et al.
Supplementary Fig. S10 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
2023 · Yu-Chen Cheng, Shayna Stein, et al.
Supplementary Fig. S1 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
2023 · Yu-Chen Cheng, Shayna Stein, et al.
PDF
Supplementary Fig. S8 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
2023 · Yu-Chen Cheng, Shayna Stein, et al.
Works count: 91
Citation count: 812
H-index: 8
I10-index: 7
Year
Topic
Type